ArticleJournal of thoracic disease2026
Association between neutrophil-to-lymphocyte ratio and risk of immune checkpoint inhibitors-related pneumonitis and radiation pneumonitis in lung cancer: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic role of neutrophil-to-lymphocyte ratio (NLR) for prediction of risk of immune checkpoint inhibitors-related pneumonitis (CIP) and radiation pneumonitis (RP) in patients with lung cancer remains unclear. This study aimed to clarify the relationship of NLR with the risk of immune CIP and RP among lung cancer patients. Methods: Web of Science, Embase, PubMed and Chinese National Knowledge Infrastructure (CNKI) databases were searched up to October 27, 2025. Odds ratios (ORs) were combined and subgroup analyses by tumor type [non-small cell lung cancer (NSCLC), lung cancer or small cell lung cancer (SCLC)] and grade of pneumonitis (all grades or grade 3 or higher) were performed. Results: Eleven studies with 2,439 patients were included and 298 (12.2%) patients experienced the CIP and/or RP. For patients receiving concurrent immunotherapy and radiotherapy, NLR was not associated with risk of pneumonitis. Pooled results demonstrated that NLR was not associated with the risk of CIP (OR =1.22, P=0.14) and subgroup analysis by tumor type also manifested negative results. However, elevated NLR was significantly related to the occurrence of severe (grade 3-5) CIP [OR =7.93, 95% confidence interval (CI): 3.51-17.92, P<0.001]. Besides, higher NLR predicted increased risk of RP (OR =2.75, 1.75-4.33, P<0.001) in NSCLC and subgroup analysis by the grade of pneumonitis showed similar positive results (all grades: OR =3.10, P<0.001; grade 3-5: OR =2.36, P=0.01). Conclusions: Based on above findings, NLR might serve as a predictor for the development of severe CIP in lung cancer and RP in NSCLC. However, more relevant studies are still needed to further clarify the predictive role of NLR for CIP and RP among lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.